The strong efficacy and durability data in a difficult-to-treat population support a potential accelerated approval pathway. Traders should watch for FDA interactions and the initiation of the Phase 3 trial in Q4 2026 as key catalysts. Given the small market cap, positive regulatory updates could drive outsized moves, but clinical and regulatory risks remain high.
Price Chart
Executive Summary
Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström macroglobulinemia patients, showing a 79.2% major response rate and median duration of response exceeding 16 months. The company plans to pursue accelerated approval and initiate a Phase 3 confirmatory trial in Q4 2026. For a $25M market cap company, this data is a significant catalyst but the path to approval remains uncertain.
Key Facts
- 79.2% major response rate (partial response or better) in 24 post-BTKi WM patients
- Median duration of response of 16 months (range: 7.3–25.4 months)
- 100% clinical benefit rate and 87.5% overall response rate
- 20% of patients exceeded 30 months duration of response
- Cytopenias were the only Grade 3+ adverse event; manageable toxicity profile
- Company plans to pursue accelerated approval in the U.S. and initiate a Phase 3 confirmatory study in Q4 2026
- Iopofosine I 131 has FDA Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations
Financial Impact
No financial figures provided; market cap ~$25M; positive data could drive significant upside if accelerated approval pathway is successful
Risk Factors
- Accelerated approval not guaranteed; FDA may require additional data
- Phase 3 confirmatory trial may fail or be delayed
- Company may need to raise capital to fund Phase 3 and operations
- Competing therapies for WM could limit commercial potential
- Small market cap and low liquidity increase volatility risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304338 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers